Related Experiment Video
Updated: Jun 9, 2026
Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
Published on: September 20, 2024
Influence of Pluronic® F68 on ceftazidime biological activity in parenteral solutions
Carolina Alves Dos Santos1, Gabriel Borghesan Ribeiro, Marcos Camargo Knirsch
1Department of Biochemical and Pharmaceutical Technology, School of Pharmaceutical Sciences, University of São Paulo, Sao Paulo, SP, Brazil. carolinasantos@usp.br
Abstract:
β-Lactam antimicrobials are known to have a low concentration/therapeutic response. However, extending the period in which β-lactam are free in the plasma does directly influence therapeutic outcomes. The objective of this study was to evaluate the influence of Pluronic® F68 on the antimicrobial activity of ceftazidime when admixed with aminophylline in parenteral solutions by the evaluation of its minimal inhibitory concentration (MIC) within 24 h. Ceftazidime, aminophylline, and Pluronics® F68 were evaluated using the MIC method against Escherichia coli and Pseudomonas aeruginosa, with these compounds individually and associated in the same parenteral solutions. When Pluronics® F68 was admixtured with ceftazidime alone or with ceftazidime and aminophylline, it was possible to observe lower MIC values not only at 24 h but also at 0 h for both microorganisms. This indicates that Pluronics® F68 may be able to enhance ceftazidime antimicrobial activity in the presence or absence of aminophylline. This fact suggests that Pluronics® F68 can be applied to allow the administration of ceftazidime under continuous infusion in parenteral solutions, beneficiating hospital pharmacotherapy. It may also be possible to reduce ceftazidime doses in formulations achieving the same therapeutic results.
Insights
Pluronic® F68 enhances the antimicrobial activity of ceftazidime in parenteral solutions, potentially improving therapeutic outcomes and allowing for reduced ceftazidime doses. This finding benefits hospital pharmacotherapy by optimizing antimicrobial treatments.
Area of Science:
- Pharmacology
- Microbiology
- Materials Science
Background:
- Beta-lactam antimicrobials exhibit a low concentration-dependent therapeutic response.
- Extended plasma-free periods of beta-lactams significantly impact therapeutic outcomes.
- Parenteral solutions require careful formulation to maintain drug efficacy.
Purpose of the Study:
- To assess the impact of Pluronic® F68 on ceftazidime's antimicrobial activity.
- To evaluate ceftazidime's efficacy when combined with aminophylline and Pluronic® F68 in parenteral solutions.
- To determine the influence on minimal inhibitory concentration (MIC) within 24 hours.
Main Methods:
- Minimal Inhibitory Concentration (MIC) method was employed.
- Evaluated ceftazidime, aminophylline, and Pluronic® F68 individually and in combination.
- Tested against Escherichia coli and Pseudomonas aeruginosa in parenteral solutions.
Main Results:
- Pluronic® F68 admixture with ceftazidime (alone or with aminophylline) reduced MIC values.
- Lower MICs were observed at both 0 and 24 hours for both tested microorganisms.
- Pluronic® F68 demonstrated enhancement of ceftazidime's antimicrobial activity.
Conclusions:
- Pluronic® F68 enhances ceftazidime's antimicrobial activity in parenteral solutions, with or without aminophylline.
- This enhancement supports continuous infusion administration of ceftazidime, optimizing hospital pharmacotherapy.
- Potential for reduced ceftazidime dosage while maintaining therapeutic efficacy.
Related Concept Videos
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
01:20Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry